Explore Turner Lab’s novel approach to developing definitive treatment for Fragile X syndrome with a Tat-conjugated, truncated FMRP protein. This innovative strategy aims to restore brain circuit function and reduce abnormal behaviors linked to Fragile X by directly addressing the cause of Fragile X: a missing protein.
Read moreUniversity of Calgary, Canada
Validating Novel Inhibitors of ERK Signalling to Treat Fragile X Syndrome
Screening and Validating Novel inhibitors of ERK Signalling to Treat Fragile X Syndrome Veronica Rasheva (undergraduate student), MoonYoung Bae (undergraduate student), Seong Eon Ha (MSc student), Asim Ahmed (MSc student), Ning Cheng (PI), Nidhi Kotikalapudi (undergraduate student), and Dorit Moehrle
Read moreReintroducing FMRP via Tat to Reduce Symptoms of Fragile X Syndrome
FRAXA Research Foundation and the Fragile X Research Foundation of Canada have awarded a grant of $100,000 over two years to Dr. Raymond Turner at the University of Calgary in Alberta, Canada. Dr. Turner and postdoctoral fellow Xiaoqin Zhan, PhD are attempting to reactivate a segment of FMRP to reverse symptoms of Fragile X in a mouse model of the disease to reduce abnormal behaviors.
Read more